Search | Clinical Trials Finder

Conditions: Clear Cell Renal Cell Carcinoma
Interventions: Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Primary Immune Deficiency
Interventions: Human Normal Immunoglobulin for Subcutaneous Administration; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Anti-human CCL24 monoclonal antibody (CM-101), Placebo; Biological · Other
Lead sponsor: ChemomAb Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: La Jolla, California • Sacramento, California • Chicago, Illinois + 4 more

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
Interventions: IMGN151; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 27 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6), Cisplatin, Gemcitabine, Carboplatin (AUC 5); Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 38
States / cities: Scottsdale, Arizona • Tucson, Arizona • Corona, California + 35 more

Conditions: Human Immunodeficiency Virus
Interventions: 10-1074-LS, 3BNC117-LS; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: BNT326, Pumitamig; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more

Conditions: Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms
Interventions: CNTO 328; Anti-interleukin-6 monoclonal antibody; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Houston, Texas

Conditions: Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
Interventions: IGIV-C, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Disease (CKD)
Interventions: Vonsetamig; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 7 more

Conditions: Coronavirus, Covid19
Interventions: bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 207
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile Myelomonocytic Leukemia (JMML), Chronic Myeloid Leukemia (CML)
Interventions: Cyclophosphamide, Fludarabine, Thiotepa, Melphalan, G-csf, Mesna, CliniMACS, ATG (rabbit), Blinatumomab, TCRα/β+, CD19+, CD45RA-depleted DLI; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Non-Small Cell Lung Cancer
Interventions: BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 6
States / cities: Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more

Conditions: Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
Interventions: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more

Conditions: Gastric Cancer, Adenocarcinoma
Interventions: ramucirumab, Placebo, Best Supportive Care (BSC); Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Bakersfield, California • La Jolla, California • Redlands, California + 11 more

Conditions: Metastatic Cancer, Epithelial Tumor
Interventions: NG-350A; Biological
Lead sponsor: Akamis Bio; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Santa Monica, California • Aurora, Colorado • New York, New York + 2 more

Conditions: Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months; Drug
Lead sponsor: Camille N. Kotton, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Primary Immune Deficiency
Interventions: IgPro20; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Centennial, Colorado • North Palm Beach, Florida • Indianapolis, Indiana + 1 more

Conditions: Facioscapulohumeral Muscular Dystrophy, FSHD
Interventions: Apitegromab, Placebo; Drug
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Symptoms of Inhalational Anthrax
Interventions: NP-015; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Malaria
Interventions: VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Breast Cancer
Interventions: Atezolizumab, Trastuzumab emtansine, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 15
States / cities: Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: Primary Immune Deficiency Disease
Interventions: Flebogamma 5% DIF; Biological
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 7
States / cities: St. Petersburg, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more

Search by objective public record fields.

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

CM-101 in PSC Patients -The SPRING Study

IVIG for Infection Prevention After CAR-T-Cell Therapy

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

ACTIV-2: A Study for Outpatients With COVID-19

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD

Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

Trial to Evaluate L9LS in Healthy Adults

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects